Medtronic's MiniMed Split-Off Nears Deadline as Clinical Wins Pile Up

Medtronic shareholders have until Oct 9, 2026, to tender shares in the MiniMed exchange offer, with the ratio set at 4.5939 MiniMed shares per Medtronic share.

Medtronic shareholders have until midnight New York time on October 9, 2026, to decide whether to tender their shares in the company's exchange offer for its MiniMed diabetes unit — a transaction that has been running alongside a steady stream of clinical and regulatory announcements from the medtech giant.

The company finalized the exchange ratio at the upper end of its indicated range: 4.5939 MiniMed shares for every Medtronic share accepted. The offer covers up to 225,361,295 MiniMed shares, and if demand exceeds that amount, an additional 27,452,053 shares could be included. Management filed the corresponding supplement with the SEC on October 7.

A Week of Clinical Disclosures

The split-off news landed in the middle of an unusually busy stretch for Medtronic's research pipeline. On October 3, the company released 24-month results from the VenaSeal Spectrum study, which showed an 88.1% ulcer healing rate in patients with advanced chronic venous disease treated with the VenaSeal closure system. The minimally invasive therapy's reimbursement footing has also improved: coverage now extends to 96% of commercially and Medicare-insured patients in the United States.

Urology data followed earlier in the week. The exploratory TITAN-2 trial demonstrated a sustained reduction in nocturia episodes over 24 months with the Altaviva system, which is designed to curb nighttime urinary urgency. To build out the evidence base further, Medtronic named Ariana L. Smith as national principal investigator for the forthcoming ENDURANCE post-approval study, while striking an awareness partnership with the American Urogynecologic Society.

Billing Codes and Regulatory Clearances

Reimbursement infrastructure for two other devices took a step forward when the American Medical Association granted Category-I CPT codes for Altaviva and the Symplicity Spyral renal denervation system, effective January 2028.

Regulatory momentum extended to Medtronic's surgical and cardiac portfolios as well. The FDA cleared the Affera Prism-2 mapping software on September 30, and the same software plus the PulseSelect ProxBox adapter with a spacing indicator received CE marking. Most recently, the agency granted 510(k) clearance for navigated ApexCut-EM blades used in sinus surgery; first U.S. clinical procedures are expected later this year once navigation software updates are in place.

Market Reaction

Investors responded positively to the combination of pipeline progress and portfolio simplification. The stock climbed 2.2% on Thursday, closing at 78.24 euros, with market observers attributing the buying interest to the prospect of a leaner corporate structure. Medtronic's market capitalization stands at 97.59 billion euros.